RxNews Recap for Friday 11-13-09 Print E-mail
By Mary Davila   
Friday, 13 November 2009 21:56

Below is a list of the companies that made news in the healthcare sector on Friday, November 13, 2009.


Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

SunLink Health Systems, Inc. (NYSE:SSY) announced earnings from continuing operations for its fiscal quarter ended September 30, 2009 of $549,000, or $0.07 per fully diluted share, compared to a loss from continuing operations of $603,000, or $0.08 per fully diluted share, for the quarter ended September 30, 2008.

Enzo Biochem Inc. (NYSE:ENZ) announced today that David Goldberg, Vice President, Corporate Development, will speak on the Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 conference in Boston, MA, on Wednesday, November 18, 2009, where Enzo’s EGS21, an orally administered beta glucosylceramide formulation, now undergoing clinical study, was named one of this year’s “top 10 inflammatory/autoimmune projects to watch.”

Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), a developer of galectin-targeted, carbohydrate therapeutic compounds to treat cancer and fibrosis, today reported its financial results for the third quarter and first nine months of fiscal 2009.

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat chronic and acute wounds, today announced that its development partners, Bayer Animal Health divisions in China and Taiwan, recently secured regulatory approvals in both those countries to develop and market Microcyn-based Vetericyn™ products for their respective animal healthcare markets.

Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced today that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference in New York City.

Ore Pharmaceutical Holdings Inc. (NASDAQ:ORXE) today reported financial results and provided an operational update for the third quarter ended September 30, 2009.

China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the research, development, manufacture, marketing and distribution of probiotics dietary supplements, today announced it will host a conference call at 11:00 a.m. EST on Tuesday, November 17, 2009, to discuss the Company's financial results for the second quarter of its 2010 fiscal year.

NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections, today reported financial results for the third quarter ended September 30, 2009.

Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the company’s executive vice president and chief financial officer, will present at Lazard’s 6th Annual Healthcare Conference at 11:00 a.m. EST / 8:00 a.m. PST on Wednesday, November 18, 2009 in New York.

Columbia Laboratories, Inc. (Nasdaq: CBRX) today commented that nothing fundamental in the Company’s operations has changed to cause the current market activity in its Common Stock.

Talecris Biotherapeutics (Nasdaq: TLCR) and N.C. Gov. Bev Perdue jointly announced today that the company will expand its manufacturing facilities in Clayton, creating 259 new jobs over the next seven years.

PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, is pleased to announce today that two of the nation's leading interventional cardiologists, Dr. Steven Yakubov and Dr. Mark Turco, have joined the Company's Scientific Advisory Board.

Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 1:40 p.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com.

Genzyme Corp. (Nasdaq:GENZ) announced today that it has issued letters to U.S. healthcare providers regarding its enzyme replacement products Cerezyme® (miglucerase for injection), Fabrazyme® (agalsidase beta), Myozyme® (alglucosidase alfa), Aldurazyme® (laronidase), as well as Thyrogen® (thyrotropin alfa for injection), filled at its Allston Landing manufacturing facility.

King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009, at 2:15 pm EST, at the St. Regis Hotel in New York, New York.

MedaSorb Technologies Corporation (OTCBB:MSBT) and its wholly-owned subsidiary, CytoSorbents, Inc., today announced the filing of Q3 2009 financial results as reported in its Form 10-Q with the SEC.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus